QTTB_OUT_1 [2025-04-03 18:57:37 -0400] 3181 Bytes | 821 tokens | Cum: 821 tkns (10.26% of 8k)
==========================================================================

We need a winner today and it's already 6:57:36 PM on Thu Apr 03, 2025 -0400 ... So let's find out if Q32 Bio (QTTB) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 1.75 up from 1.485. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: Q32 Bio (QTTB)
IPO: 2024-03-26 (1 Year Ago)
Market Cap: $19,516,184
Shares Outstanding: 12,200,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Here's the first list of news for Q32 Bio:

C1 - Mar-11-25 06:59AM - Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
C2 - Mar-08-25 11:00AM - Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
C3 - Feb-28-25 09:00AM - Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
C4 - Feb-26-25 06:59AM - Q32 Bio to Participate in Upcoming March Investor Conferences
C5 - Feb-10-25 04:05PM - Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
C6 - Feb-04-25 04:05PM - Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
C7 - Dec-12-24 07:45AM - Q32 Bio price target lowered to $20 from $80 at Oppenheimer
C8 - Dec-11-24 04:11PM - Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Q32 Bio (QTTB)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

QTTB_OUT_3 [2025-04-03 18:57:42 -0400] 1098 Bytes | 300 tokens | Cum: 1123 tkns (14.04% of 8k)
==========================================================================

Showing C1 (chunk 1 of 8): C1:
**Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update**
Date: Mar-11-25 06:59AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/q32-bio-reports-fourth-quarter-2024-financial-results-and-provides-corporate-update-302397587.html

-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting --

-- Advancing bempikibart in patients with AA, with SIGNAL-AA open-label extension (OLE) and SIGNAL-AA Part B on track to dose patients in 1H'25; SIGNAL-AA Part B topline data on-track for 1H'26 --

-- Cash and cash equivalents of$78.0 millionas ofDecember 31, 2024expected to provide financial runway into 2H'26 --

WALTHAM,

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

QTTB_OUT_5 [2025-04-03 18:57:43 -0400] 937 Bytes | 280 tokens | Cum: 1519 tkns (18.99% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-11T11:33:04Z - Q32 Bio: Q4 Earnings Snapshot - WTOP News...
A2 - 2025-03-11T11:10:35Z - Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update - Q32 Bio (NASDA...
A3 - 2025-03-09T22:30:17Z - Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart...
A4 - 2025-03-09T22:15:34Z - Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients wit...
A5 - 2025-03-08T17:54:00Z - Q32 Bio Presents Additional Results From Phase 2a Trial Of Bempikibart In Alopecia Areata...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

QTTB_OUT_7 [2025-04-03 18:57:46 -0400] 1023 Bytes | 310 tokens | Cum: 1831 tkns (22.89% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
**Q32 Bio: Q4 Earnings Snapshot - WTOP News**Date: 2025-03-11Source: {'uri': 'wtop.com', 'dataType': 'news', 'title': 'WTOP'}URL: https://wtop.com/news/2025/03/q32-bio-q4-earnings-snapshot/WALTHAM, Mass. (AP) -- WALTHAM, Mass. (AP) -- Q32 Bio Inc. (QTTB) on Tuesday reported a loss of $14.2 million in its fourth quarter.

The Waltham, Massachusetts-based company said it had a loss of $1.16 per share.

For the year, the company reported a loss of $47.7 million, or $6.58 per share.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on QTTB at https://www.zacks.com/ap/QTTB

Copyright © 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

QTTB_OUT_9 [2025-04-03 18:57:47 -0400] 420 Bytes | 111 tokens | Cum: 2008 tkns (25.10% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-04-15T18:11:35Z - Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

QTTB_OUT_11 [2025-04-03 18:57:51 -0400] 1100 Bytes | 297 tokens | Cum: 2307 tkns (28.84% of 8k)
==========================================================================

Showing B1 (chunk 1 of 3): B1:
**Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/04/38255428/why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mShares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday.
Here are some other stocks moving in today's mid-day session.
Gainers

Soligenix, Inc. (NASDAQ: SNGX) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVa

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

QTTB_OUT_13 [2025-04-03 18:57:52 -0400] 797 Bytes | 198 tokens | Cum: 2624 tkns (32.80% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-11 8-K Item 2.02 Results of Oper and Fin Cond.

On March 11, 2025, Q32 Bio Inc. announced its financial results for the quarter ended December 31, 2024 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished a...

S2 - 2025-03-11 10-K Item 7. Mgts Disc ussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis of our financial condition and results of operations should be read together with our CONS financial statements and the related notes ap...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

QTTB_OUT_15 [2025-04-03 18:57:56 -0400] 1041 Bytes | 259 tokens | Cum: 2885 tkns (36.06% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02 Results of Operations and Financial Condition.

On March 11, 2025, Q32 Bio Inc. announced its financial results for the quarter ended December 31, 2024 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

QTTB_OUT_17 [2025-04-03 18:58:15 -0400] 19958 Bytes | 5368 tokens | Cum: 8379 tkns (104.74% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-------------------------+
| Volume: 409,664 | Perf Month: -28.73% | Option/Short: Yes / Yes | Sales Y/Y TTM: -100.00% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 219.09K | Perf Quarter: -53.49% | Short Float: 22.82% | ROE: -121.36% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 1.87 | Index: RUT | Short Ratio: 4.60 | ROI: -228.75% |
+---------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 30.44 | Market Cap: 19.51M | Short Interest: 1.01M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.22 | Shs Outstand: 12.20M | Beta: -0.02 | EPS Surprise: 24.20% |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA20: -17.19% | Shs Float: 4.42M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -34.60% | Inst Own: 36.52% | Sales past 5Y: 184.31% | Earnings: Mar 11 BMO |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -93.17% | Insider Own: 63.80% | Employees: 42 | |
+---------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: -15.34% | Insider Trans: 0.00% | Debt/Eq: 3.33 | |
+---------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Q32 Bio Inc. (QTTB) by Manke Isaac (Unknown Title) on 2025-01-15
- Stock Option (Right to Buy): 12767 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 12767 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 2627 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 2627 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 19008 shares at $0 (D) Footnote: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported.
- Stock Option (Right to Buy): 19008 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 19008 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

Inside Trans: Q32 Bio Inc. (QTTB) by Kalowski Lee (CFO and President) on 2025-02-24
- Common Stock: 53250 shares at $0 (D) Footnote: The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2025 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock.
- Stock Option (Right to Buy): 16901 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 16901 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 161323 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 161323 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

Inside Trans: Q32 Bio Inc. (QTTB) by LAPORTE KATHLEEN (Unknown Title) on 2025-02-24
- Stock Option (Right to Buy): 5431 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 5431 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 1947 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 1947 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 12767 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 12767 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

Inside Trans: Q32 Bio Inc. (QTTB) by TZIANABOS ARTHUR (Unknown Title) on 2025-02-24
- Stock Option (Right to Buy): 25674 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 25674 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 12767 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 12767 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

Inside Trans: Q32 Bio Inc. (QTTB) by Thistle Mary (Unknown Title) on 2025-02-24
- Stock Option (Right to Buy): 12767 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 12767 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

Inside Trans: Q32 Bio Inc. (QTTB) by GRAYZEL DAVID S. (Unknown Title) on 2025-01-15
- Stock Option (Right to Buy): 12767 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 12767 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 2569 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 2569 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 18595 shares at $0 (D) Footnote: This option was granted to the Reporting Person, a director of the Issuer pursuant to the 2024 Plan and pursuant to the Issuer's non-employee director compensation policy. This option represents the Reporting Person's election to receive stock options in lieu of cash retainer fees Due to administrative oversight this option award initially was not reported. This option shall vest in four equal quarterly installments as of the last date of each calendar quarter subject to the Reporting Person's continued board service through such date.
- Stock Option (Right to Buy): 18595 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 18595 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

Inside Trans: Q32 Bio Inc. (QTTB) by Campagna Jason (Chief Medical Officer) on 2025-02-24
- Common Stock: 37500 shares at $0 (D) Footnote: The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2025 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock.
- Stock Option (Right to Buy): 87738 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 87738 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 17951 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 17951 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 70687 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 70687 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

Inside Trans: Q32 Bio Inc. (QTTB) by Iwicki Mark T (Unknown Title) on 2025-02-24
- Stock Option (Right to Buy): 37222 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 37222 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 7615 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 7615 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 25534 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- Stock Option (Right to Buy): 25534 shares at $0 (D) Footnote: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -47733000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.6
Average Volume: 166016.83
30-Day High: 2.33
30-Day Low: 1.485

[Detailed Financials: TTM 2024]
- Total Assets: $92,332,000.0
- Total Liabilities: $86,657,000.0
- Total Equity: $5,675,000.0
- Current Assets: $81,877,000.0
- Current Liabilities: $16,465,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -5.12

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $47,348,000.0

[Detailed Financials: FY 2024]
- Total Assets: $92,332,000.0
- Total Liabilities: $86,657,000.0
- Total Equity: $5,675,000.0
- Current Assets: $81,877,000.0
- Current Liabilities: $16,465,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -5.12

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $47,348,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

QTTB_OUT_19 [2025-04-03 18:58:19 -0400] 676 Bytes | 167 tokens | Cum: 8796 tkns (109.95% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

QTTB_IN_21 [2025-04-03 18:58:19 -0400] 126 Bytes | 29 tokens | Cum: 8897 tkns (111.21% of 8k)
==========================================================================

====================================
[2025-04-03 18:58:19] # Analysis Completed
Elapsed Time: 43.17 seconds